Financials

v2.4.0.8
Consolidated Balance Sheets (USD $)
Dec. 31, 2013
Dec. 31, 2012
Current assets:    
Cash and cash equivalents $ 10,048,466 $ 25,652,083
Short-term investments 305,538 2,633,944
Accounts receivable 458,391 41,896
Other current assets 344,386 1,078,040
Total current assets 11,156,781 29,405,963
Equipment, net 457,912 986,553
Restricted cash 2,921,724 1,577,920
Other long-term assets 159,224 39,597
Total assets 14,695,641 32,010,033
Current liabilities:    
Accounts payable 794,397 1,523,875
Accrued expenses 2,445,446 2,410,592
Deferred revenue 1,069,438 3,314,918
Accrued warrant liability 1,241,311 4,105,659
Current portion of note payable 351,527  
Current portion of capital lease obligation 83,634 71,679
Total current liabilities 5,985,753 11,426,723
Noncurrent portion of capital lease obligation 7,522 97,602
Long-term debt 7,121,388  
Commitments and contingencies      
Total liabilities 13,114,663 11,524,325
Stockholders' equity:    
Preferred stock, $.005 par value; 10,000,000 shares authorized, 0 shares issued and outstanding as of December 31, 2013 and December 31, 2012, respectively      
Common stock, $.005 par value; 160,000,000 shares authorized, 45,182,114 shares issued and outstanding as of December 31, 2013; 80,000,000 shares authorized, 44,730,445 issued and outstanding as of December 31, 2012 225,911 223,653
Additional paid-in capital 125,508,471 123,864,830
Accumulated other comprehensive income 307,339 546,473
Accumulated deficit (135,564,666) (118,301,789)
Total Cleveland BioLabs, Inc. stockholders' (deficit) equity (9,522,945) 6,333,167
Noncontrolling interest in stockholders' equity 11,103,923 14,152,541
Total stockholders' equity 1,580,978 20,485,708
Total liabilities and stockholders' equity $ 14,695,641 $ 32,010,033
v2.4.0.8
Consolidated Statements of Operations (USD $)
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Revenues:      
Grants and contracts $ 8,487,966 $ 3,570,710 $ 8,790,209
Operating expenses:      
Research and development 19,525,950 22,501,805 22,788,887
General and administrative 12,038,775 11,115,511 11,106,493
Total operating expenses 31,564,725 33,617,316 33,895,380
Loss from operations (23,076,759) (30,046,606) (25,105,171)
Other income:      
Interest and other income (expense) 83,127 (70,015) 53,659
Change in value of warrant liability 2,864,348 7,701,981 19,821,787
Total other income 2,947,475 7,631,966 19,875,446
Net loss (20,129,284) (22,414,640) (5,229,725)
Net loss attributable to noncontrolling interests 2,866,407 4,180,498 1,216,055
Net loss attributable to Cleveland BioLabs, Inc. $ (17,262,877) $ (18,234,142) $ (4,013,670)
Net loss available to common stockholders per share of common stock, basic and diluted $ (0.38) $ (0.49) $ (0.12)
Weighted average number of shares used in calculating net loss per share, basic and diluted 45,002,823 37,388,847 32,561,743
v2.4.0.8
Consolidated Statements of Cash Flows (USD $)
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Cash flows from operating activities:      
Net income (loss) $ (20,129,284) $ (22,414,640) $ (5,229,725)
Adjustments to reconcile net income (loss) to net cash used in operating activities:      
Depreciation 376,213 479,595 512,366
Amortization 94,995   13,147
Unrealized currency loss on short-term investments   52,726  
(Gain) loss on equipment disposal (3,222) 18,997  
Impairment loss on property and equipment 293,162    
Noncash compensation 1,473,449 2,535,217 4,044,858
Warrant issuance costs   244,857 150,827
Change in value of warrant liability (2,864,348) (7,701,981) (19,821,787)
Patent costs     1,481,318
Changes in operating assets and liabilities:      
Accounts receivable (416,495) 1,736,199 3,641,491
Other current assets 697,966 (182,428) 123,197
Other long-term assets (29,732) (6,414) (919)
Accounts payable (713,502) 609,522 (348,282)
Deferred revenue (2,062,332) 3,238,124 (2,317,218)
Accrued expenses 180,483 740,723 845,337
Net cash used in operating activities (23,102,647) (20,649,503) (16,905,390)
Cash flows from investing activities:      
Purchase of short-term investments   (5,220,781) (5,520,000)
Sale of short-term investments 2,197,940 8,312,120 434,835
Purchase of equipment (139,491) (178,271) (655,553)
Increase in restricted cash (1,497,740) (1,541,366)  
Investment in patents     (326,171)
Net cash provided by (used in) investing activities 560,709 1,371,702 (6,066,889)
Cash flows from financing activities:      
Issuance of common stock, net of offering costs   15,675,727 21,946,801
Net proceeds from issuance of debt 7,327,675    
Exercise of options 12,392 2,375 532,408
Repayment of capital lease obligation (78,125) (52,410)  
Exercise of warrants     949,793
Net cash provided by financing activities 7,261,942 21,519,249 34,769,442
Effect of exchange rate change on cash and cash equivalents (323,621) 538,046 156,889
Increase (decrease) in cash and cash equivalents (15,603,617) 2,779,494 11,954,052
Cash and cash equivalents at beginning of period 25,652,083 22,872,589 10,918,537
Cash and cash equivalents at end of period 10,048,466 25,652,083 22,872,589
Supplemental disclosure of cash flow information:      
Cash paid during the period for interest 128,811 23,708  
Supplemental schedule of noncash financing activities:      
Fair value of warrants issued in connection with debt 117,999    
Equipment acquired through lease financing   221,690  
Conversion of warrant liability to equity upon warrant exercise     995,428
Noncash financing costs on common stock offering     207,905
Noncash warrant issuance costs     19,361
Incuron, LLC [Member]
     
Cash flows from financing activities:      
Noncontrolling interest capital contribution   5,893,557 2,340,374
Panacela [Member]
     
Cash flows from financing activities:      
Noncontrolling interest capital contribution     $ 9,000,066
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue